Incyclinide
Based on 12 publication(s) in Google Scholar
Incyclinide (CMT-3, COL-3) is a matrix metalloproteinase (MMP) inhibitor and inhibiting angiogenesis, tumor growth and invasion, and metastasis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.51%
- No. CAS: 15866-90-7
- Fòrmula: C19H17NO7
- Peso molecular:371.34
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-COVID-19 Compound Library
HY-L052
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Pain-Related Compound Library
HY-L139
-
Protease Inhibitor Library
HY-L147
-
Cysteine Targeted Covalent Library
HY-L153
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Incyclinide
More- Sci Adv. 2023 Jan 20;9(3):eadd3867. [Abstract]
- Proc Natl Acad Sci U S A. 2023 Apr 25;120(17):e2218522120. [Abstract]
- EMBO Rep. 2023 Dec 6;24(12):e57228. [Abstract]
- ACS Biomater Sci Eng. 2025 Feb 10;11(2):916-929. [Abstract]
- Cells. 2021 Aug 22;10(8):2163. [Abstract]
- Molecules. 2023 May 23;28(11):4262. [Abstract]
- Sci Rep. 2025 May 6;15(1):15762. [Abstract]
- In Vitro Model. 2025 Mar 7;4(1):59-69. [Abstract]
- bioRxiv. 2026 Jan 11:2026.01.09.698733. [Abstract]
- University of Minnesota. 2024.
- bioRxiv. 2023 Oct 12:2023.05.06.539698. [Abstract]
- Authorea. May 19, 2021.
Actividad biológica
Incyclinide has been shown to experimentally suppress prostate cancer, colon adenocarcinoma and melanoma invasiveness in cell culture. Adding incyclinide at final concentrations of 5 to 20 μM inhibits MT1-MMP gelatinolytic and caseinolytic activity, blocks MT1-MMPactivation of pro-MMP-2, and decreases invasiveness of HT-1080 fibrosarcoma cells[1]. Incyclinide is an especially effective inhibitor of the growth and viability of filamentous fungi. Most of the MICs of CMT-3 against filamentous fungi are found to be between 0.25 and 8 μg/mL, and the inhibition of viability of these fungi by incyclinide is routinely higher than 90%[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 15866-90-7
-
Appearance Solid
-
Peso molecular 371.34
-
Fòrmula C19H17NO7
-
Color Light yellow to yellow
-
SMILES
O=C(C(C1=O)=C(O)C[C@]2([H])C[C@]3([H])CC4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4)N
-
Synonyms
CMT-3; COL-3
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Sci Adv
2023 Jan 20;9(3):eadd3867. PMID: 36662861 -
Proc Natl Acad Sci U S A
Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling. [Abstract]2023 Apr 25;120(17):e2218522120. PMID: 37068243 -
EMBO Rep
Tetracyclines activate mitoribosome quality control and reduce ER stress to promote cell survival. [Abstract]2023 Dec 6;24(12):e57228. PMID: 37818824 -
ACS Biomater Sci Eng
2025 Feb 10;11(2):916-929. PMID: 39792458 -
Cells
The Chemically-Modified Tetracycline COL-3 and Its Parent Compound Doxycycline Prevent Microglial Inflammatory Responses by Reducing Glucose-Mediated Oxidative Stress. [Abstract]2021 Aug 22;10(8):2163. PMID: 34440932 -
Molecules
Scope and Limitations of Exploiting the Ability of the Chemosensitizer NV716 to Enhance the Activity of Tetracycline Derivatives against Pseudomonas aeruginosa. [Abstract]2023 May 23;28(11):4262. PMID: 37298737 -
Sci Rep
Pharmacological alternatives to oxytetracycline as potential treatment of flexural limb deformities in foals: a preliminary in vitro cell viability and proliferation study. [Abstract]2025 May 6;15(1):15762. PMID: 40328831 -
In Vitro Model
An in vitro model to measure the strength and stiffness of the extracellular matrix synthesized de novo by human fibroblasts. [Abstract]2025 Mar 7;4(1):59-69. PMID: 40160211 -
bioRxiv
Atypical tetracyclines promote longevity and ferroptotic neuroprotection via translation attenuation. [Abstract]2026 Jan 11:2026.01.09.698733. PMID: 41542485 -
-
bioRxiv
Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue. [Abstract]2023 Oct 12:2023.05.06.539698. PMID: 37425811 -
Solvente y solubilidad
DMSO : ≥ 100 mg/mL (269.29 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.73 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
Determination of C. albicans growth inhibition by CMT-3 is carried out by a modified turbidity assay. A series of tubes containing PDB (5 mL) and different concentrations of incyclinide (0, 0.125, 0.25, 0.5, 1.0, and 2.0 μg/mL) are each inoculated with a 100 μL suspension of C. albicans in late log phase to yield a final cell concentration of 106/mL. The tubes are aerobically incubated at 35°C, and at each time point (0, 1, 2, 4, 6, 12, and 24 h), the turbidity in each tube is determined spectrophotometrically at 600 nm[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats: Eighteen Wistar rats receive a standardized orthodontic appliance at one side of the maxilla. During 14 days, three groups of six rats receive a daily dose of 0, 6 or 30 mg/kg incyclinide, and tooth displacement is measured. Thereafter, osteoclasts are counted on histological sections using an ED-1 staining. Multi- and mononuclear ED-1-positive cells in the PDL are also counted. In addition, sections are stained for MMP-9[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Lee HM, et al. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMPactivity: relevance to cancer. Curr Med Chem. 2001 Feb;8(3):257-60. [Content Brief]
[2]. Liu Y, A chemically modified tetracycline (CMT-3) is a new antifungal agent. Antimicrob Agents Chemother. 2002 May;46(5):1447-54. [Content Brief]
[3]. Bildt MM, et al. CMT-3 inhibits orthodontic tooth displacement in the rat. Arch Oral Biol. 2007 Jun;52(6):571-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6929 mL | 13.4647 mL | 26.9295 mL | 67.3237 mL |
| 5 mM | 0.5386 mL | 2.6929 mL | 5.3859 mL | 13.4647 mL | |
| 10 mM | 0.2693 mL | 1.3465 mL | 2.6929 mL | 6.7324 mL | |
| 15 mM | 0.1795 mL | 0.8976 mL | 1.7953 mL | 4.4882 mL | |
| 20 mM | 0.1346 mL | 0.6732 mL | 1.3465 mL | 3.3662 mL | |
| 25 mM | 0.1077 mL | 0.5386 mL | 1.0772 mL | 2.6929 mL | |
| 30 mM | 0.0898 mL | 0.4488 mL | 0.8976 mL | 2.2441 mL | |
| 40 mM | 0.0673 mL | 0.3366 mL | 0.6732 mL | 1.6831 mL | |
| 50 mM | 0.0539 mL | 0.2693 mL | 0.5386 mL | 1.3465 mL | |
| 60 mM | 0.0449 mL | 0.2244 mL | 0.4488 mL | 1.1221 mL | |
| 80 mM | 0.0337 mL | 0.1683 mL | 0.3366 mL | 0.8415 mL | |
| 100 mM | 0.0269 mL | 0.1346 mL | 0.2693 mL | 0.6732 mL |
Incyclinide Related Classifications
HY-13648 Related Classifications
Powered by Bioz